CG Oncology, Inc. Common stock (CGON)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $6.65B
Last updated: Nov 17, 2026 at 11:05 AM ET
CG Oncology, Inc. Common stock (CGON) Stock Forecast
Analysts expect CG Oncology, Inc. Common stock (CGON) to earn -$2.96 per share in the fiscal year ending Dec 31, 2026, on revenue of $4.54M. Of 15 analysts, 14 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 10 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 15 ratings average 1.80, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 93% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 4 | 26.7% |
| Buy | 10 | 66.7% |
| Hold | 1 | 6.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 15
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 2095.6%.
- Fiscal year ending Dec 31, 2026
- -$2.96
- EPS consensus, revenue $4.54M
- Fiscal year ending Dec 31, 2027
- -$2.78
- EPS consensus, revenue $99.68M
- Next report
- Feb 25, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$2.96 | -$3.14 to -$2.41 | 11 | $4.54M | $3.80M to $6.06M | 12 |
| Dec 31, 2027 | -$2.78 | -$4.38 to -$1.85 | 12 | $99.68M | N/A | 11 |
Quarterly Estimates
The EPS consensus rises from -$0.84 for the quarter ending Dec 31, 2026 to -$0.74 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.84 | -$1.01 to -$0.62 | 16 | $644303 | N/A | 14 |
| Mar 31, 2027 | -$0.74 | -$0.80 to -$0.66 | 3 | $400000 | N/A | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 17 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 10 |
| Fiscal year ending Dec 31, 2027 | 2 | 7 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$3.22.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$2.96 | -$3.23 | -$3.23 | -$3.20 | -$3.22 | N/A |
| Fiscal year ending Dec 31, 2027 | -$2.78 | -$3.02 | -$3.02 | -$3.02 | -$2.90 | N/A |
| Quarter ending Mar 31, 2027 | -$0.74 | -$0.89 | -$0.89 | -$0.89 | -$0.89 | N/A |
Frequently Asked Questions About CGON
What is the CGON stock forecast?
Consensus analyst estimates put CG Oncology, Inc. Common stock's EPS at -$2.96 for the fiscal year ending Dec 31, 2026, on revenue of $4.54M. The consensus rating from 15 analysts is Buy.
How do analysts rate CGON stock?
Of 15 analysts covering CG Oncology, Inc. Common stock, 4 rate it Strong Buy, 10 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from CGON next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$2.96, with estimates from -$3.14 to -$2.41 from 11 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$2.78, with estimates from -$4.38 to -$1.85 from 12 analysts.
What revenue do analysts expect from CG Oncology, Inc. Common stock next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $4.54M, with estimates from $3.80M to $6.06M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $99.68M.
How many analysts cover CGON?
15 analysts rate CG Oncology, Inc. Common stock stock, and 11 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CGON pages: Overview, Earnings, Forecast, Financials, Competitors